Status:
COMPLETED
NEURodevelopmental Outcome After Persistent Pulmonary Hypertension Of the Newborn
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Persistent Pulmonary Hypertension of the Newborn
Eligibility:
All Genders
1-5 years
Phase:
NA
Brief Summary
Neonatal pulmonary hypertension is a rare but serious condition resulting from a lack of adaptation to extra-uterine life in some newborns. In the short term, the risk of death requires rapid and appr...
Eligibility Criteria
Inclusion
- All parenting authority holders of children aged 1 to 5 years, born after 34 weeks of amenorrhea and having been cared for neonatal PAH in paediatric resuscitation
Exclusion
- Holders of parental authority who cannot answer the questionnaire because they do not speak French.
- Opposition of one of the two holders of parental authority
- Minor parental authority holders
- Holders of parental authority under safeguarding of justice, guardianship or guardianship
- Newborns with neonatal PAH with an associated diagnosis of diaphragmatic hernia or cyanogenic congenital heart disease
- Newborns with neonatal PAH not treated with nitrogen monoxide
Key Trial Info
Start Date :
July 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 29 2021
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT04841070
Start Date
July 25 2021
End Date
October 29 2021
Last Update
November 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Toulouse
Toulouse, France